Optimization Of Raw Material Procurement In DXI Company

Compared with chemical drugs,biologic drugs have better pesticide effect,less toxicity and are not prone to develop resistance,so biologic drugs have broad prospect.In the past few years,China’s biologic drugs have developed particularly rapidly.The market growth rate is much higher than not only the growth rate of chemical drugs,but also the growth rate of global biologic drugs.However,with the rapid development,many management issues are gradually exposed,such as high dependence on upstream suppliers and unstable supply chain,which has brought great challenges to the healthy and sustainable development of biologic drugs in China.How to maintain the continuous and stable supply of materials has become a common concern of all enterprises.Firstly,this thesis starting from the particularity and importance of biopharmaceutical material procurement,then analyzes various issues encountered in DXI company,and finds specialization of procurement personnel is insufficient,procurement positions do not implement differentiated management,approval of purchase orders takes a long time,improper selection of procurement ways and unscientific supplier management are the main issues encountered in DXI company.Secondly,this thesis tries to solve these issues by constructing position competency model,recombing approval process,classified and management of materials,developing suppliers in multiple ways and classified and management of suppliers.Finally,to implement these measures smoothly,this thesis attempts to put forward safeguard measures from improving procurement management,supervision of management process,training,and build corporate culture.It is hoped that by analyzing the issues existing in the procurement of production materials of DXI company,it can provide solutions for the procurement optimization of other similar companies and help the company to develop healthy and stable.